---
title: "Moderna, Inc. Inc (MRNA.US) Q1 2022 Earnings Call"
description: "Moderna, Inc. is committed to the development of revolutionary messenger ribonucleic acid (mRNA) therapeutics. Its product line includes prophylactic vaccines, "
locale: "en"
url: "https://longbridge.com/en/lives/11452"
parent: "https://longbridge.com/en/lives.md"
category: "Earnings Call"
---

# Moderna, Inc. Inc (MRNA.US) Q1 2022 Earnings Call

**Status**: Unknown
**Category**: Earnings Call

## Description

Moderna, Inc. is committed to the development of revolutionary messenger ribonucleic acid (mRNA) therapeutics. Its product line includes prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, local regeneration therapy, systemic secretion therapy, and systemic intracellular therapy. The company was founded in 2010 by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose, and Kenneth R. Chien and is headquartered in Cambridge, Massachusetts.

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.